Bone/Mineral Metabolism News

Endocrine Today has compiled a list of the top five news stories posted from the American Association of Clinical Endocrinologists Scientific & Clinical Congress, held April 24-28, 2019, in Los Angeles.

LOS ANGELES — The approval of new agents for postmenopausal women with osteoporosis at high risk for fracture and for children and adults with a rare, inherited form of rickets were two of several exciting developments in bone research during the past year, according to a speaker here.

LOS ANGELES — Adults on permanent hemodialysis have a lower lumbar spine trabecular bone score, independent of bone mineral density score, when compared with healthy controls, likely explaining the increased risk for osteoporotic fracture observed in these patients, according to study data presented here.

During a long and groundbreaking career, Felicia Cosman, MD, has earned a place of distinction in the field of osteoporosis research and the overall endocrinology field. For her work with anabolic medications and other important breakthroughs in osteoporosis treatments, she has won numerous awards.

LOS ANGELES — Older adults with type 2 diabetes, particularly those with longer disease duration and those taking diabetes medications, had increased 1- and 2-year fracture risks vs. adults without diabetes, but the risks evened out by 10 years, according to study results presented at the AACE Annual Scientific and Clinical Congress.

LOS ANGELES — When it comes to optimal bone health and fracture prevention, there is scant evidence for recommending supplementation with vitamins and minerals other than calcium and vitamin D, according to a speaker at the AACE Annual Scientific and Clinical Congress.

In this video exclusive, Susan Samson, MD, PhD, FRCPC, FACE, associate professor in the department of endocrinology, diabetes and metabolism at Baylor College of Medicine in Houston and program chair for the American Association of Clinical Endocrinologists annual meeting describes highlights of this year’s sessions.

The FDA in February signaled its support for customizable solutions for people with diabetes with two new device approvals designed to improve automated insulin delivery, suggesting that more personalized artificial pancreas systems may become reality sooner rather than later.

The overall evidence indicates that drug therapies for osteoporosis reduce the risk for clinical fractures, but long-term use may increase the risk for rare, but serious harms, according to findings published in Annals of Internal Medicine.

Endocrine Today has compiled a list of recent FDA news stories relating to endocrine practice. Drugs under consideration included those for osteoporosis, diabetes, overweight and obesity, hypoactive sexual desire disorder and hypogonadism.